Clarification25 Aug 2026, 10:58 am
Bal Pharma Clarifies 18-Month Tenure for Convertible Warrants
AI Summary
Bal Pharma Ltd has issued a clarification regarding the allotment of Convertible Warrants on a preferential basis. The company confirms that the tenure of these warrants, and consequently the timeline for the utilization of net proceeds, is 18 months from the date of allotment. This clarification is in accordance with SEBI regulations and is subject to stock exchange approval. Bal Pharma emphasizes that there are no changes to the objects of the preferential issue or the manner of fund utilization.
Key Highlights
- Convertible warrants have an 18-month tenure from allotment.
- Net proceeds utilization timeline aligns with warrant tenure.
- No changes in the objects of the preferential issue.
- Clarification issued in accordance with SEBI regulations.
Price Impact
More from BALPHARMA